Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2015-09-23

Clinical Trial Update: Relevance of Flavanols for Cardiovascular Function in End-Stage Renal Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating flavanols for cardiovascular function in end-stage renal disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Flavanols (flavanols)

Snippet

Sponsor: RWTH Aachen University | Conditions: End Stage Renal Disease | Phase 2 | Status: WITHDRAWN